Letters, Statements & Analysis
AMCP communicates the importance of managed care pharmacy by collaborating with members to provide comments, analysis, and testimony to Congress and federal and state agencies on the impact of proposed regulations and laws on managed care pharmacy and patients.
The Academy of Managed Care Pharmacy (AMCP) acknowledges that abuse deterrent opioid analgesic drug products are appropriate for certain patients. However, we are opposed to House Bill 1698 because it would mandate coverage for these products on every formulary, and restrict a health insurance plan’s ability to use utilization review requirements to determine the appropriate use of these products.
The Academy of Managed Care Pharmacy (AMCP) thanks the Food and Drug Administration (FDA) for the opportunity to provide comments on the reauthorization of the Biosimilar User Fee Act (BsUFA) for fiscal years 2018 through 2022 as published in the Federal Register on September 13, 2016. These written comments are provided in addition to the oral comments AMCP will present at the public meeting on October 20, 2016.
The Academy of Managed Care Pharmacy (AMCP) thanks the Institute of Clinical and Economic Review (ICER) for the opportunity to provide comments on the draft scoping document that will examine the clinical effectiveness and value of abuse-deterrent formulation (ADF) of opioids in pain management released on September 8, 2016. AMCP appreciates the broad input from payers as well as patients, pain management specialists, and pharmaceutical manufacturers.
The Academy of Managed Care Pharmacy (AMCP) thanks the Institute of Clinical and Economic Review (ICER) for the opportunity to provide comments in response to the national call for suggestions on how to improve its value assessment framework released on July 14, 2016.
The Academy of Managed Care Pharmacy (AMCP) urges you to sign Assembly Bill 1114, legislation that would make certain pharmacist provided services a covered benefit under the Medi-Cal program. As health care delivery in the United States continues to evolve and the focus on an interdisciplinary team approach to patient care increases, it is critical to recognize the value of pharmacists as health care providers.
The Academy of Managed Care Pharmacy (AMCP) respectfully requests that you support Assembly Bill 1114 that would make certain pharmacist provided services a covered benefit under the MediCal program. As health care delivery in the United States continues to evolve and the focus increases on an interdisciplinary team approach to patient care, it is critical to recognize the value of pharmacists as health care providers.
The undersigned pharmacist organizations thank the Food and Drug Administration (FDA) for the opportunity to provide comments on the reauthorization of the Prescription Drug User Fee Act (PDUFA) for fiscal years (FY) 2018 through 2022 as published in the Federal Register on July 19, 2016. Collectively, our organizations represent over 100,000 pharmacists across the full spectrum of health care practice settings.
The Academy of Managed Care Pharmacy (AMCP) supports the passage of House Bill 2041. This legislation would recognize pharmacists as health care providers and authorize them to perform certain patient services including drug therapy management and administering drugs and biological products to a patient pursuant to a physician’s orders. As health care delivery in the United States continues to evolve and the focus increases on an interdisciplinary team approach to patient care, it critical to achieve better quality patient care that pharmacists are recognized as health care providers.
The Academy of Managed Care Pharmacy (AMCP) opposes House Bill 976. This bill would amend Chapter 112 Section 12EE (a) by replacing the words “biosimilar and interchangeable” in the definition of “interchangeable biologic product” with the words “therapeutically equivalent to”. This new proposed definition is inconsistent with existing Massachusetts law, which follows the language in the Biologics and Price Competition and Innovation Act (BPCIA).
The Academy of Managed Care Pharmacy (AMCP) recognizes the value of medication synchronization as one tool that may improve adherence. However, we urge you to oppose Assembly Bill 2050 because it would mandate synchronization of medications without the benefit of industry input and a study of existing programs.
The Academy of Managed Care Pharmacy (AMCP) thanks the Food and Drug Administration (FDA) for the opportunity to provide comments in response to the draft guidance document titled “Labeling for Biosimilar Products: Guidance for Industry” published in the Federal Register on April 4, 2016.
AMCP is writing to express concern about proposals by the Food and Drug Administration (FDA) and a provision included in Section 11 of the “FDA and NIH Workforce Authorities Modernization Act” (S. 2700) that would exempt certain biological products, including biosimilars, from the requirement to adhere to U.S. Pharmacopeial (USP) public standards for quality, including the naming of biologic and biosimilar medicines.
